About - PRFX :

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Employees - 7, CEO - Dr. Ehud Geller Ph.D., Sector - Healthcare, Country - IL, Market Cap - 1.49M

Altman ZScore(max is 10): -44.24, Piotroski Score(max is 10): 1, Working Capital: $-1899000, Total Assets: $3107000, Retained Earnings: $-54681000, EBIT: -17826000, Total Liabilities: $5148000, Revenue: $0

- Current Price $5.30 - Analyst Target Price $48.00

Stats & Key Metrics
TickerPRFX
Index-
Curent Price 5.30
Change-52.51%
Market Cap1.49M
Average Volume3.10M
Income-17.67M
Sales0.00M
Book Value/Share-0.59
Cash/Share9.95
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees7
Moving Avg 20days51.15%
Moving Avg 50days79.99%
Moving Avg 200days-59.77%
Shares Outstanding3.47M
Earnings DateNov 12
Inst. Ownership2.47%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales-
Price/Book-
Price/Cash0.53
Price/FCF-
Quick Ratio0.61
Current Ratio0.61
Debt/Equity-
Return on Assets-309.43%
Return on Equity-716.67%
Return on Investment-
Gross Margin-
Ops Margin-
Profit Margin-
RSI54.80
BETA(β)0.48
From 52week Low206.86%
From 52week High-93.43%
Earnings & Valuation
EPS-8.29
EPS next Year-48.24
EPS next Qtr-7.68
EPS this Year53.92%
EPS next 5 Year-
EPS past 5 Year-28.81%
Sales past 5 Year0.00%
EPS Y/Y9.41%
Sales Y/Y-
EPS Q/Q-3.64%
Sales Q/Q-
Sales Surprise-
EPS Surprise0.00%
ATR(14)2.00
Perf Week70.42%
Perf Month27.40%
Perf Quarter113.71%
Perf Year-91.11%
Perf YTD-91.97%
Target Price48.00

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer